Business & Finance
BIOCORP partners with MERCK for Mallya for Human Growth Hormone (HGH)
16 September 2021 -

French medical company BIOCORP (FR0012788065 – ALCOR) said on Thursday that it will develop and supply a specific version of its Mallya device to monitor treatment adherence to Human Growth Hormone (HGH) under an agreement with Merck.

Manufactured in Clermont-Ferrand (France), Mallya is a Bluetooth enabled clip-on device for pen injectors that collects dose and time of each injection and transfers information in real time to a companion software.

Mallya is the first in its category to receive the CE-mark (medical device) and commercial versions for insulin pen injectors are already available and distributed in Europe and other geographies.

The partners will develop a specific version of Mallya for applications in the field of Human Growth Hormone (HGH) . The device will help patients (children and teenagers) automatically keep track of their HGH daily injection and monitor adherence with their treatment plan.

In conjunction with the agreement, Merck will pay around EUR3m for the development of the specific solution.

Following the development phase, BIOCORP will manufacture the commercial units for the global market on behalf of Merck, which will generate additional revenues.